Company: LGNZZ
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000886163-25-000012
Chunk: 9

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1
Chunk 9
---
AlvogenWomen's Health25%-40% 2$8.2$30.2VaxneuvanceMerckInfectious DiseaseLow single digit$5.2$791.3PneumosilSerum InstituteInfectious DiseaseLow single digit$3.8$161.5NexteroneBaxterCardiovascularLow single digit$2.8$70.1Ohtuvayre 3VeronaRespiratory Disease3%$2.7$41.6CapvaxiveMerckInfectious DiseaseLow single digit$0.6$95.7TzieldSanofiMetabolic DiseaseLess than 1%$0.2$58.019 Other Products$8.5Total Royalty Receipts$119.6Less: Amortization of Financial Royalty Assets4$10.8GAAP Income from Royalty Assets$108.8

NOTES:

(1) Based on our agreement with Recordati, sales of Qarziba are undisclosed.

(2) We receive tiered profit sharing of 25% on quarterly profits less than $3.75 million, 35% on quarterly profits greater than $3.75 million but less than $7.5 million and 40% on quarterly profits greater than $7.5 million. If therapeutic equivalence is achieved, quarterly profit changes to 50% of quarterly profits.

(3) Ohtuvayre royalty receipts include an allocation of contractually earned milestones and royalties pertaining to financial royalty assets.

(4) Amounts represent the adjustments to the effective interest income recognized to total contractual payments recognized in the period. 

Major Commercial-Stage Royalty Receipt Generating Assets

The following programs represent important revenue-generating components of our current portfolio. For information about the royalties owed to us for certain of these programs, see “Royalties” later in this business section.

6

Kyprolis (Amgen, Ono, BeiGene)

We supply Captisol to Amgen for use with Kyprolis (carfilzomib) and granted Amgen an exclusive product-specific license under our patent rights with respect to Captisol. Kyprolis is formulated with Ligand’s Captisol technology and is approved for the following:

•In combination with dexamethasone, lenalidomide plus dexamethasone, daratumumab plus dexamethasone, or daratumumab and hyaluronidase-fihj and d